Processa Pharmaceuticals, Inc. (PCSA)
USD 0.94
(-6.67%)
USD 0.94
(-6.67%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.06 Million | -9.6 Million | -8.71 Million | -3.14 Million | -2.75 Million | -3.7 Million |
| Net Income | -11.12 Million | -27.42 Million | -11.42 Million | -14.41 Million | -3.35 Million | -3.76 Million |
| Depreciation & Amortization | 222.00 | 788.49 Thousand | 790.97 Thousand | 803.77 Thousand | 803.77 Thousand | 630.09 Thousand |
| Deferred income taxes | 15.93 Thousand | - | -530.61 Thousand | -1 Million | -602.71 Thousand | -902.8 Thousand |
| Stock-based compensation | 1.06 Million | 8.82 Million | 3.4 Million | 2.73 Million | 510.47 Thousand | 74.06 Thousand |
| Change in working capital | 605.2 Thousand | 543.6 Thousand | -1.17 Million | -140.39 Thousand | -179.71 Thousand | 188.71 Thousand |
| Other non-cash items | 1.37 Million | 7.65 Million | 220.6 Thousand | 8.87 Million | 75.9 Thousand | 67.06 Thousand |
| Investing Cash Flow | -2776.00 | - | - | - | - | -22.28 Thousand |
| Investments in PPE | -2776.00 | - | - | - | - | -20.5 Thousand |
| Acquisitions | - | - | - | - | - | -1782.00 |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | -1782.00 |
| Financing Cash Flow | 6.26 Million | -388.84 Thousand | 9.79 Million | 17.86 Million | 1.7 Million | 2.62 Million |
| Debt repayment | - | - | - | -862.45 Thousand | -805 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 1.31 Million | -388.84 Thousand | -64.39 Thousand | -95.21 Thousand | - | - |
| Common Stock Issuance | 6.32 Million | - | 10.04 Million | 17.1 Million | - | 2.87 Million |
| Other Financing Activities | -52.74 Thousand | -88.84 Thousand | -186.49 Thousand | 2.49 Million | 2.5 Million | -250.95 Thousand |
| Accounts receivables | - | 70.27 Thousand | 6750.00 | -77.02 Thousand | - | - |
| Accounts payables | -15.93 Thousand | 108.64 Thousand | -101.78 Thousand | 245.08 Thousand | -216.49 Thousand | 241.41 Thousand |
| Inventory | - | -70.27 Thousand | -6750.00 | 77.02 Thousand | - | - |
| Other working capital | 621.13 Thousand | 434.96 Thousand | -1.07 Million | -385.47 Thousand | 36.77 Thousand | -52.7 Thousand |
| Cash at beginning of period | 6.5 Million | 16.49 Million | 15.41 Million | 691.53 Thousand | 1.74 Million | 2.84 Million |
| Cash at end of period | 4.7 Million | 6.5 Million | 16.49 Million | 15.41 Million | 691.53 Thousand | 1.74 Million |
| Capital Expenditure | -2776.00 | - | - | - | - | -20.5 Thousand |
| Effect of forex changes on cash | -1.00 | - | - | - | - | - |
| Net cash flow / Change in cash | -1.79 Million | -9.99 Million | 1.08 Million | 14.72 Million | -1.04 Million | -1.1 Million |
| Free Cash Flow | -8.06 Million | -9.6 Million | -8.71 Million | -3.14 Million | -2.75 Million | -3.72 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.38 Million | -3.01 Million | -2.72 Million | -11.12 Million | -2.4 Million | -2.08 Million |
| Depreciation & Amortization | 203.00 | 139.00 | 139.00 | 222.00 | 140.00 | 82.00 |
| Deferred income taxes | - | - | - | 15.93 Thousand | -291.78 Thousand | - |
| Stock-based compensation | 154.19 Thousand | 152.63 Thousand | 167.64 Thousand | 1.06 Million | 256.81 Thousand | 142.89 Thousand |
| Change in working capital | 21.22 Thousand | -509.57 Thousand | 488.34 Thousand | 605.2 Thousand | 3127.00 | 157.46 Thousand |
| Other non-cash items | -393.52 Thousand | -323.51 Thousand | 45.54 Thousand | 1.37 Million | 312.75 Thousand | 20.57 Thousand |
| Investing Cash Flow | -3244.00 | - | - | -2776.00 | - | -2776.00 |
| Investments in PPE | -3243.00 | -1.00 | - | -2776.00 | - | -2776.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -1.00 | - | - | - | - | - |
| Financing Cash Flow | 926.19 Thousand | -3414.00 | 6.26 Million | 6.26 Million | -30.6 Thousand | -52.74 Thousand |
| Debt repayment | -1437.00 | -1406.00 | -895.00 | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 11.93 Thousand | -2008.00 | -9924.00 | 1.31 Million | 52.74 Thousand | -52.74 Thousand |
| Common Stock Issuance | 939.85 Thousand | - | 6.27 Million | 6.32 Million | -30.6 Thousand | - |
| Other Financing Activities | -24.15 Thousand | -2008.00 | -9924.00 | -52.74 Thousand | -52.74 Thousand | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -241.37 Thousand | 497.71 Thousand | 143.75 Thousand | -15.93 Thousand | -34.68 Thousand | 107.27 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 662.69 Thousand | -1 Million | 344.59 Thousand | 621.13 Thousand | 37.8 Thousand | 50.18 Thousand |
| Cash at beginning of period | 5.57 Million | 8.92 Million | 4.7 Million | 6.5 Million | 6.86 Million | 8.67 Million |
| Cash at end of period | 2.89 Million | 5.57 Million | 8.92 Million | 4.7 Million | 4.7 Million | 6.86 Million |
| Capital Expenditure | -3243.00 | -1.00 | - | -2776.00 | - | -2776.00 |
| Effect of forex changes on cash | - | - | - | -1.00 | - | - |
| Net cash flow / Change in cash | -2.67 Million | -3.34 Million | 4.21 Million | -1.79 Million | -2.15 Million | -1.81 Million |
| Free Cash Flow | -3.6 Million | -3.34 Million | -2.04 Million | -8.06 Million | -2.12 Million | -1.76 Million |
0SAY
KOHINOOR
KLINIQ
XPG
002117
TIIL